Working with TipRanks
Follow Us
Stock Ideas
Daily Updates
Calendars
Education
About Us
Working with TipRanks
Follow Us
Crispr Therapeutics AG (GB:0VRQ)
LSE:0VRQ
Crispr Therapeutics AG (0VRQ) Share Price & Analysis
0 Followers
0VRQ Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$39.30 - $86.33
Previous Close$64.21
Volume1.28K
Average Volume (3M)2.50K
Market Cap
$5.13B
Enterprise Value$3.49B
Total Cash (Recent Filing)$1.88B
Total Debt (Recent Filing)$240.27M
Price to Earnings (P/E)-9.6
Beta1.04
Next Earnings
Aug 08, 2023EPS Estimate
-$2.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.72
Shares Outstanding78,935,098
10 Day Avg. Volume1,090
30 Day Avg. Volume2,504
Standard Deviation0.25
R-Squared0.02
Alpha0.06
Financial Highlights & Ratios
Price to Book (P/B)2.73
Price to Sales (P/S)132.42
Price to Cash Flow (P/CF)143.60
P/FCF Ratio143.60
Enterprise Value/Market CapN/A
Enterprise Value/Revenue34.79
Enterprise Value/Gross Profit-31.76
Enterprise Value/Ebitda-6.63
Forecast
1Y Price Target
$75.00Price Target Upside16.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering18
Crispr Therapeutics AG News
0VRQ FAQ
What was Crispr Therapeutics AG’s price range in the past 12 months?
Crispr Therapeutics AG lowest share price was $39.30 and its highest was $86.33 in the past 12 months.
What is Crispr Therapeutics AG’s market cap?
Currently, no data Available
When is Crispr Therapeutics AG’s upcoming earnings report date?
Crispr Therapeutics AG’s upcoming earnings report date is Aug 08, 2023 which is in 64 days.
How were Crispr Therapeutics AG’s earnings last quarter?
Crispr Therapeutics AG released its earnings results on May 08, 2023. The company reported -$0.67 earnings per share for the quarter, beating the consensus estimate of -$1.741 by $1.071.
Is Crispr Therapeutics AG overvalued?
According to Wall Street analysts Crispr Therapeutics AG’s price is currently Undervalued.
Does Crispr Therapeutics AG pay dividends?
Crispr Therapeutics AG does not currently pay dividends.
What is Crispr Therapeutics AG’s EPS estimate?
Crispr Therapeutics AG’s EPS estimate is -$2.13.
How many shares outstanding does Crispr Therapeutics AG have?
Crispr Therapeutics AG has 78,935,100 shares outstanding.
What happened to Crispr Therapeutics AG’s price movement after its last earnings report?
Crispr Therapeutics AG reported an EPS of -$0.67 in its last earnings report, beating expectations of -$1.741. Following the earnings report the stock price went up 8.976%.
Which hedge fund is a major shareholder of Crispr Therapeutics AG?
Among the largest hedge funds holding Crispr Therapeutics AG’s share is ARK Investment Management LLC. It holds Crispr Therapeutics AG’s shares valued at 361M.
---
Crispr Therapeutics AG Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$75.00 (16.81% Upside)
$75.00 (16.81% Upside)
Blogger Sentiment
Bullish
GB:0VRQ Sentiment 100%
Sector Average 71%
Sector Average 71%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
6.55%
12-Months-Change
Fundamentals
Return on Equity
-25.56%
Trailing 12-Months
Asset Growth
-13.88%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Crispr Therapeutics AG
CRISPR Therapeutics AG engages in the development and commercialization of therapies derived from genome-editing technology. Its proprietary platform CRISPR/Cas9-based therapeutics allows for precise and directed changes to genomic DNA. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow in 2014 and is headquartered in Zug, Switzerland.
---
Crispr Therapeutics AG
―
MoonLake Immunotherapeutics
―
VectivBio Holding
―
Bluebird Bio
―
Sangamo Biosciences
―
---